Cargando…

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

We reviewed preclinical data and clinical development of MDM2 (murine double minute 2), ALK (anaplastic lymphoma kinase) and PARP (poly [ADP-ribose] polymerase) inhibitors. MDM2 binds to p53, and promotes degradation of p53 through ubiquitin-proteasome degradation. JNJ-26854165 and RO5045337 are 2 s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Yuan, Liao, Yu-Min, Hsueh, Chung-Tsen, Mirshahidi, Hamid R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103487/ https://www.ncbi.nlm.nih.gov/pubmed/21504625 http://dx.doi.org/10.1186/1756-8722-4-16

Ejemplares similares

Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature
por: Shaheen, Shagufta, et al.
Publicado: (2018)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

Updates in non-small cell lung cancer - insights from the 2009 45(th )annual meeting of the American Society of Clinical Oncology
por: Mirshahidi, Hamid R, et al.
Publicado: (2010)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
por: Min, Ahrum, et al.
Publicado: (2020)

Is autophagy induction by PARP inhibitors a target for therapeutic benefit?
por: ELSHAZLY, AHMED M., et al.
Publicado: (2022)

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
por: Fang, Yuan, et al.
Publicado: (2020)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

PARP1 Inhibition as a Novel Therapeutic Target for Keloid Disease
por: Park, Tae Hwan, et al.
Publicado: (2019)

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
por: Zhu, Haohao, et al.
Publicado: (2022)

Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials
por: Hsueh, Chung-Tsen, et al.
Publicado: (2013)

MDM2 inhibitors-mediated disruption of mitochondrial metabolism: A novel therapeutic strategy for retinoblastoma
por: Romani, Arianna, et al.
Publicado: (2022)

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
por: Chan, Wei Yen, et al.
Publicado: (2021)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
por: Wang, Hui Qin, et al.
Publicado: (2017)

Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors
por: Poddubskaya, Elena, et al.
Publicado: (2019)

MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
por: Miles, Xanthene, et al.
Publicado: (2021)

Targeted therapy in head/neck and gastric cancers
por: Hsueh, Chung-Tsen
Publicado: (2012)

Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting
por: Dadone-Montaudié, Bérengère, et al.
Publicado: (2020)

PARP inhibitors: current status and implications for anticancer therapeutics
por: Usmani, Hadi, et al.
Publicado: (2013)

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
por: Alhusaini, Abdullah, et al.
Publicado: (2021)

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
por: Sim, Hao-Wen, et al.
Publicado: (2022)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Targeted and novel therapy in advanced gastric cancer
por: Selim, Julie H., et al.
Publicado: (2019)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

Novel ALK inhibitors in clinical use and development
por: Iragavarapu, Chaitanya, et al.
Publicado: (2015)

Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors
por: Yang, Dafu, et al.
Publicado: (2021)

A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib
por: Khan, Nawazish A., et al.
Publicado: (2014)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer
por: Dasa, Siva Sai Krishna, et al.
Publicado: (2018)

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
por: Lim, Joline S. J., et al.
Publicado: (2017)

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
por: Vikas, Praveen, et al.
Publicado: (2020)

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
por: Kim, Dae-Seok, et al.
Publicado: (2021)

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
por: Van Goethem, Alan, et al.
Publicado: (2017)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

Recent advancements in PARP inhibitors-based targeted cancer therapy
por: Zhou, Ping, et al.
Publicado: (2020)

CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma
por: An, Rong, et al.
Publicado: (2016)

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK
por: Di Paolo, Daniela, et al.
Publicado: (2015)

Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas
por: Li, Hongyi, et al.
Publicado: (2020)

Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides
por: Aubry, Arthur, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r11mvj9m07i8gsaf1qlr9chiln